Endemic in over Endemic in
100 Countries[3] over 100
Countries[3]
86 Countries
now show evidence
OF ZIKA VIRUS INFECTION[2] now show
evidence OF
ZIKA VIRUS INFECTION[2]

­estimated $60.3 BILLION

­estimated
$60.3 BILLION
ANNUAL ECONOMIC
IMPACT WORLDWIDE[2]

ANNUAL ECONOMIC
IMPACT WORLDWIDE[2]

Scroll
Down

THE NUMBERS ARE CHANGING

THE NUMBERS ARE CHANGING

Take a closer look at worldwide infectious disease facts and statistics. Take a closer look at worldwide infectious
disease facts and statistics.
world map
  • Dengue
    Map shows areas at risk for dengue transmission.
  • Zika
    Map shows areas that have or have had Zika transmission.
  • Norovirus
    Map shows areas with the risk of norovirus transmission.
  • Dengue facts

    About 50% of the world's population lives under the threat of dengue, which is responsible for approximately 390 million infections globally per year.[3]

  • Dengue facts

    Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries.[3]

  • Zika facts

    As of July 2018, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.[1]

  • Zika facts

    As of March 2017, a decline in cases of Zika infection has been reported in some countries, or in some parts of countries; WHO advises that vigilance needs to remain high.[1]

  • Norovirus facts

    Norovirus is the most common viral cause of acute gastroenteritis worldwide, responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis.[2]

  • Norovirus facts

    Norovirus is estimated to cause more than 699 million illness cases each year.[2]

  • Interested in
    Learning More?

    For updated disease information and statistics, please visit the following websites:

    Back to disease facts and statistics

vaccines change numbers

If all children were

immunized

with existing

vaccines, by 2020

we would

save nearly

25,000,000

lives

If all children were immunized with

existing vaccines,

by 2020 we would

save nearly

25,000,000 lives[6]

Estimated

2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus,

pertussis (whooping cough), and measles

Estimated 2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus, pertussis (whooping cough), and measles [7]

vaccines change lives

infectious diseases
that need our attention

infectious diseases that
need our attention

Learn about some of the diseases we are focusing on. Learn about some of the diseases
we are focusing on.
slide image

DENGUE

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.[3]

slide image

ZIKA

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.[1]

slide image

NOROVIRUS

About the disease:

Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.[8]

slide image

DENGUE

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.[3]

slide image

ZIKA

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.[1]

slide image

NOROVIRUS

About the disease:

Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.[8]

WHO WE ARE

WHO WE ARE

OUR VISION

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

  • Fairness
  • Honesty
  • Integrity
  • Perseverence

OUR PRODUCTS

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN
  • BLB-750 (H5N1 Flu)
  • Measles Rubella
  • Mumps
  • Diphtheria Tetanus Toxoid
  • Seasonal Flu (Denka & Kaketsuken)
  • Varicella (Biken)
  • Japanese Encephalitis (Biken)
 

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

  • Fairness
  • Honesty
  • Integrity
  • Perseverence

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN
  • BLB-750 (H5N1 Flu)
  • Measles Rubella
  • Mumps
  • Diphtheria Tetanus Toxoid
  • Seasonal Flu (Denka & Kaketsuken)
  • Varicella (Biken)
  • Japanese Encephalitis (Biken)
 

WE'RE COMMITTED
TO A HEALTHIER FUTURE

WE'RE COMMITTED
TO A HEALTHIER FUTURE

Here's what we are working on: Here's what we are working on:
View Clinical Trials
slide image

DENGUE

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

slide image

NOROVIRUS

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus genotypes is being developed.

Development Phase: Phase 2b

slide image

ZIKA

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

View Clinical Trials
slide image

DENGUE

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

slide image

NOROVIRUS

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus genotypes is being developed.

Development Phase: Phase 2b

slide image

ZIKA

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

NEWSROOM

NEWSROOM:
WE'RE MAKING PROGRESS

Takeda is taking steps towards making an impact on public
health by developing innovative new vaccines. Takeda is taking steps towards making an
impact on public health by developing
innovative new vaccines.

Visit the Takeda Vaccines Newsroom for news releases, videos and infographics.

Swipe to see the five most recent press releases from the Takeda Vaccine Business.

Click the arrows to see the five most recent press releases from the Takeda Vaccine Business.

April 19, 2022

Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

Read the full story
Read the full story
September 07, 2021

Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

Read the full story
Read the full story
July 29, 2021

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Read the full story
Read the full story
July 20, 2021

Takeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Government

Read the full story
Read the full story
May 22, 2021

Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by
Long-Term Safety and Efficacy Results

Read the full story
Read the full story
May 21, 2021

Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan

Read the full story
Read the full story
March 25, 2021

Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

Read the full story
Read the full story

 


leading the way

leading the way

Meet the people who are committed to making change. Meet the people who are committed
to making change.
Takeda Vaccine Business Leadership
Takeda Vaccine Business Leadership
Our team is working passionately toward improving public health.
Click to meet our leaders Swipe to meet our leaders
Explore Takeda Careers
slide image

Gary Dubin, MD

President, Takeda Vaccine Business

Gary is President of the Takeda Vaccine Business. He joined Takeda in 2015 and led the Global Medical Office before assuming his current role in 2022. Gary has more than 30 years of experience in vaccine research. Before joining Takeda, he spent the previous 20 years at GSK Vaccines.

slide image

Joseph Santangelo, PhD

Head of Global CMC

Joe is Head of Global CMC for the Takeda Vaccine Business. He is a biotech entrepreneur who previously started two vaccine development companies, Microscience and SingVax (later merged with Inviragen and acquired by Takeda Vaccines in May 2013). Joe has more than 35 years of research and technology experience in cell biology, infectious diseases and industrial microbiology.

slide image

Rogerio Ribeiro

Head of Commercial

Rogerio is Head of Commercial for the Takeda Vaccine Business. Before joining Takeda, Rogerio spent more than 20 years at GSK, holding various leadership positions including Senior Vice President and Head of Global Health Unit, Head of Emerging Markets Region, and Senior Vice President & Area Head, Latin America.

slide image

Tom Hensey, MSc MBA

Head of Commercial Manufacturing & Supply

Tom is the Head of Commercial Manufacturing & Supply for the Takeda Vaccine Business, and joined Takeda in 2016. His prior experience in vaccines includes strategy and operations roles at Novartis and Seqirus. He previously worked at McKinsey & Co. in the US and Japan, and in engineering roles at Merck.   

slide image

Amy Atwood

Head of Vaccine Communications

Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid.

slide image

Kay Oishi

Head of Human Resources

Kay is the Head of Human Resources for the Takeda Vaccine Business. He joined Takeda in 2006 and worked in Takeda’s R&D organization before joining the Vaccine business. Kay has more than 20 years of HR experience, and worked at NEC Corporation prior to Takeda.  

slide image

Rupa Cornell, JD

Head Counsel

Rupa is Head Counsel for the Takeda Vaccine Business. She has been practicing law for over 20 years. Prior to joining Takeda, Rupa held legal positions with increasing responsibilities at various biotech companies including Stealth BioTherapeutics, Sage Therapeutics, Biogen and Boston Scientific Corporation.

slide image

Anita Rehberger

Head of Global Vaccine Quality

Anita is Head of Global Vaccine Quality for the Takeda Vaccine Business. She joined Takeda in 2017. Anita has more than 20 years of Quality Management and Quality Control industry experience with vaccine, recombinant and plasma- derived product development and commercial supply from her time at Baxter and Pfizer. 

slide image

Fabien Jolly

Head of Data, Digital & Technology

Fabien is Head of Data, Digital and Technology for the Takeda Vaccine Business. He joined Takeda in 2017. Fabien has more than 20 years of experience in managing global Information Technology organizations in the biopharmaceutical industry from his time at Shire and Sanofi Aventis where he worked closely with the Sanofi Pasteur vaccines division.

slide image

Inge LeFevre, MD

Head of Vaccine Development

Inge is Head of Vaccine Development for the Takeda Vaccine Business. She joined Takeda in 2017 and most recently has served as Head of Global Regulatory Affairs, Vaccines. Inge has more than 20 years of experience in Clinical Development, Regulatory Affairs and Pharmacovigilance across all global markets and stages of vaccine development. Prior to joining Takeda, Inge worked at GSK Vaccines.

slide image

Dieter Gniel

Head of Global Medical Affairs

Dieter is Head of Global Medical Affairs for the Takeda Vaccine Business. He joined Takeda in 2014. Prior to Takeda, Dieter has held global and regional medical affairs roles at Novartis Vaccines and Chiron Vaccines.

slide image

Andrea Bertolotti-Ciarlet, PhD

Head of Vaccine Research and Analytics

Andrea is Head of Vaccine Research and Analytics for the Takeda Vaccine Business. Prior to joining Takeda in 2016, she worked at Merck and Biogen. Andrea has more than 20 years of experience in research, drug discovery and development.

slide image

Matt Symonds

Chief Financial Officer

Matt is the Chief Financial Officer for the Takeda Vaccine Business. He joined Takeda in 2011 and has held various global financial leadership roles across the company. Matt has more than 20 years of experience in the industry, including his prior role as an investment banker focused in biopharma.

Explore Takeda Careers

Our team is working passionately toward improving public health.

Swipe to meet our leaders
slide image

Gary Dubin, MD

President, Takeda Vaccine Business

Gary is President of the Takeda Vaccine Business. He joined Takeda in 2015 and led the Global Medical Office before assuming his current role in 2022. Gary has more than 30 years of experience in vaccine research. Before joining Takeda, he spent the previous 20 years at GSK Vaccines.

slide image

Joseph Santangelo, PhD

Head of Global CMC

Joe is Head of Global CMC for the Takeda Vaccine Business. He is a biotech entrepreneur who previously started two vaccine development companies, Microscience and SingVax (later merged with Inviragen and acquired by Takeda Vaccines in May 2013). Joe has more than 35 years of research and technology experience in cell biology, infectious diseases and industrial microbiology.

slide image

Rogerio Ribeiro

Head of Commercial

Rogerio is Head of Commercial for the Takeda Vaccine Business. Before joining Takeda, Rogerio spent more than 20 years at GSK, holding various leadership positions including Senior Vice President and Head of Global Health Unit, Head of Emerging Markets Region, and Senior Vice President & Area Head, Latin America.

slide image

Tom Hensey, MSc MBA

Head of Commercial Manufacturing & Supply

Tom is the Head of Commercial Manufacturing & Supply for the Takeda Vaccine Business, and joined Takeda in 2016. His prior experience in vaccines includes strategy and operations roles at Novartis and Seqirus. He previously worked at McKinsey & Co. in the US and Japan, and in engineering roles at Merck.   

slide image

Amy Atwood

Head of Vaccine Communications

Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid.

slide image

Kay Oishi

Head of Human Resources

Kay is the Head of Human Resources for the Takeda Vaccine Business. He joined Takeda in 2006 and worked in Takeda’s R&D organization before joining the Vaccine business. Kay has more than 20 years of HR experience, and worked at NEC Corporation prior to Takeda.  

slide image

Rupa Cornell, JD

Head Counsel

Rupa is Head Counsel for the Takeda Vaccine Business. She has been practicing law for over 20 years. Prior to joining Takeda, Rupa held legal positions with increasing responsibilities at various biotech companies including Stealth BioTherapeutics, Sage Therapeutics, Biogen and Boston Scientific Corporation.

slide image

Anita Rehberger

Head of Global Vaccine Quality

Anita is Head of Global Vaccine Quality for the Takeda Vaccine Business. She joined Takeda in 2017. Anita has more than 20 years of Quality Management and Quality Control industry experience with vaccine, recombinant and plasma- derived product development and commercial supply from her time at Baxter and Pfizer. 

slide image

Fabien Jolly

Head of Data, Digital & Technology

Fabien is Head of Data, Digital and Technology for the Takeda Vaccine Business. He joined Takeda in 2017. Fabien has more than 20 years of experience in managing global Information Technology organizations in the biopharmaceutical industry from his time at Shire and Sanofi Aventis where he worked closely with the Sanofi Pasteur vaccines division.

slide image

Inge LeFevre, MD

Head of Vaccine Development

Inge is Head of Vaccine Development for the Takeda Vaccine Business. She joined Takeda in 2017 and most recently has served as Head of Global Regulatory Affairs, Vaccines. Inge has more than 20 years of experience in Clinical Development, Regulatory Affairs and Pharmacovigilance across all global markets and stages of vaccine development. Prior to joining Takeda, Inge worked at GSK Vaccines.

slide image

Dieter Gniel

Head of Global Medical Affairs

Dieter is Head of Global Medical Affairs for the Takeda Vaccine Business. He joined Takeda in 2014. Prior to Takeda, Dieter has held global and regional medical affairs roles at Novartis Vaccines and Chiron Vaccines.

slide image

Andrea Bertolotti-Ciarlet, PhD

Head of Vaccine Research and Analytics

Andrea is Head of Vaccine Research and Analytics for the Takeda Vaccine Business. Prior to joining Takeda in 2016, she worked at Merck and Biogen. Andrea has more than 20 years of experience in research, drug discovery and development.

slide image

Matt Symonds

Chief Financial Officer

Matt is the Chief Financial Officer for the Takeda Vaccine Business. He joined Takeda in 2011 and has held various global financial leadership roles across the company. Matt has more than 20 years of experience in the industry, including his prior role as an investment banker focused in biopharma.

1World

It's the single thing that
that connects us all

YOU ARE ABOUT TO LEAVE THIS WEBSITE AND ENTER A WEBSITE OPERATED BY AN INDEPENDENT THIRD PARTY

The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities on those websites will be governed by the policies and practices of those third parties.

Please select "Continue" if you wish to be taken to this third-party website.